Enliven Therapeutics, Inc. is a high-risk pharmaceutical company based in the United States of America. Specializing in precision oncology, Enliven focuses on developing innovative therapies to target specific issues in cancer treatment such as tolerability, combinability, resistance, and disease escape, especially in brain metastases. Their product candidates, including ELVN-001 and ELVN-002, aim to provide groundbreaking solutions in the field of oncology. With an ESG score of 30.9, Enliven Therapeutics is paving the way for cutting-edge precision oncology treatments.